On July 3, 2025, Suzhou Linaxin Biotechnology Co., Ltd. and Linyi Zhengzheng Hospital jointly announced that the Linaxin Early Screening Demonstration Center for Cancer Prevention has officially landed at Zhengzheng Hospital.

Both parties will rely on the early screening project for digestive tract tumors to provide accurate and efficient cancer screening services for residents in Linyi area, helping to solve the health problem of "low early diagnosis rate".

As a high-tech enterprise focusing on the fourth-generation nanopore gene detection technology, Suzhou Linaxin Biotechnology Co., Ltd. has shown its technical advantages in digestive tumor detection with its “Li-ChangLight” and other early screening products. Linyi Zhengzhi Hospital, as a second-level comprehensive hospital integrating medical treatment, rehabilitation and health management, has a team of gastroenterology experts and advanced diagnostic and treatment equipments such as GE, Philips, etc., and has accumulated a profound experience in the field of diagnosis and treatment of digestive system diseases. This cooperation realizes the deep integration of biotechnology and clinical resources.

At the launch meeting, Dr. Tan Shengwei, a biomedical doctor of LinaCore, said that he would explore a new model of home early screening with Zhengzhi Hospital through the combined DNA methylation detection technology of multiple gene mutations, so that the advanced technology could benefit more people.

The president of ZhengZhi Hospital emphasized that the demonstration center will practice the concept of “good health care, upright service” and realize “early screening and early treatment” of tumors by relying on Linaxin technology. Test expert Yu Ruizhen popularized the knowledge of early screening of bowel cancer and explained the clinical value of non-invasive testing technology.